Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:52 PM
Ignite Modification Date:
2025-12-24 @ 11:52 PM
NCT ID:
NCT04980651
Eligibility Criteria:
Inclusion Criteria:
* 1\) Age≥18 years, regardless of sex.
* 2\) Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 72 hours of stroke onset.
* 3\) Baseline NIHSS ≥ 4, ≤ 24.
* 4\) Baseline mRS ≤ 2;
* 5\) Signed and dated informed consent is obtained.
Exclusion Criteria:
* 1\) Patients who undergo thrombolytic therapy or endovascular treatment.
* 2\) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture, or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc.
* 3\) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumors,s and other diseases involving the brain.
* 4\) Pregnant or lactating women.
* 5\) Previous remote ischemic conditioning therapy or similar treatment.
* 6\) Severe hepatic and renal dysfunction.
* 7\) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons.
* 8\) Unwilling to be followed up or treated for poor compliance.
* 9\) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission.
* 10\) Other conditions that the researchers think are not suitable for the group.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04980651
Study Brief:
Protocol Section:
NCT04980651